Skip to main content
. Author manuscript; available in PMC: 2016 Jun 27.
Published in final edited form as: Transl Res. 2015 Sep 18;166(6):554–567. doi: 10.1016/j.trsl.2015.09.004

Table 2. Effect of Bleomycin (BLM) on inflammatory markers and oxidative stress in the lung.

Vascular endothelial growth factor (VEGF) mRNA expression decreased in lungs from BLM mice compared to mice receiving saline; BLM mice treated with yASCs did not differ from BLM mice treated with oASCs. Infusion of yASC inhibited BLM-induced increase in tumor necrosis factor alpha (TNFα) mRNA expression; these mice had the same TNFα expression as saline controls. An age associated increase in lung ROS was inhibited only by infusion of yASC, not oASCs. BLM induced a reduction of lung nuclear factor erythroid 2-related factor 2 (Nrf2) mRNA expression compared to saline treatment, which was inhibited by infusion of yASCs. Transforming growth factor beta (TGFβ) also demonstrated a BLM-induced increase, which was inhibited by yASC infusion.

Treatment Groups VEGF mRNA/18S TNFα mRNA/18S ROS Nrf2 mRNA/18S TGFβ mRNA/18S
Saline, n=3–6 4.54±0.78 0.18±0.09 18.5±0.68 19.0±3.65 6.57±1.80
BLM, n=5–11 0.51±0.04a 3.43±1.02a 18.6±0.52 8.47±1.11a 19.5±2.49a
BLM+yASC, n=3–8 1.01±0.33a 0.80±0.34b 13.3±1.25a,b 18.3±1.83b 2.63±1.47b
BLM+oASC, n=5–11 0.61±0.11a 0.38±0.07a,b 18.4±1.20 c 8.82±1.24a,c 18.0±3.17c
a

p<0.05 compared to saline;

b

p<0.05 compared to BLM;

c

compared to yASC. Values are expressed as mean ± standard error of mean.